Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.49 |
| ▸ | ITGAV | P06756 | 14/20 | 0.49 |
| ▸ | ITGB6 | P18564 | 12/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.49 |
| ▸ | ITGB8 | P26012 | 4/20 | 0.49 |
| ▸ | ITGA8 | P53708 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6777933 | 0.84 | ITGB3 (0.64) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7835946 | 0.82 | ITGB3 (0.51) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6774023 | 0.82 | ITGB3 (0.49) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6783032 | 0.81 | ITGB3 (0.72) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| Trifluoroacetic Acid SCHEMBL3835291 | 0.80 | ITGB3 (0.51) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6776952 | 0.80 | ITGB3 (0.49) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL242674 | 0.79 | ITGB3 (0.55) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6778768 | 0.78 | ITGB3 (0.60) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7835684 | 0.78 | ITGB3 (0.48) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6776866 | 0.78 | ITGB3 (0.53) | ITGB3ITGAVITGB6ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |